Citigroup’s Immunocore IMCR Stock Holding History

Citigroup’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$909K	Hold	30,000	–	–	﹤0.01%	3393
2026 Q2	$952K	Buy	30,000 +5,000	+20%	+$148K	﹤0.01%	3478
2026 Q1	$754K	Hold	25,000	–	–	﹤0.01%	3296
2025 Q4	$868K	Sell	25,000 -49,600	-66%	-$1.75M	﹤0.01%	3223
2025 Q3	$2.71M	Sell	74,600 -30,000	-29%	-$1.02M	﹤0.01%	2417
2025 Q2	$3.28M	Buy	104,600 +49,600	+90%	+$1.54M	﹤0.01%	2255
2025 Q1	$1.63M	Buy	55,000 +30,000	+120%	+$900K	﹤0.01%	2890
2024 Q4	$738K	Hold	25,000	–	–	﹤0.01%	3582
2024 Q3	$778K	Hold	25,000	–	–	﹤0.01%	3455
2024 Q2	$847K	Buy	+25,000	New	+$1.28M	﹤0.01%	3027
2024 Q1	–	Sell	-25,000	Closed	-$1.71M	–	5742
2023 Q4	$1.71M	Buy	+25,000	New	+$1.3M	﹤0.01%	2377
2023 Q3	–	Sell	-11,000	Closed	-$660K	–	5722
2023 Q2	$660K	Buy	+11,000	New	+$628K	﹤0.01%	3163

Other funds holding IMCR

Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $33B AUM 30.04% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $296B AUM 23.14% 1-Year Est. Return

JHC

Jones Hill Capital New York $589M AUM

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Citigroup's IMCR Position: Q3 2026 in Review

Citigroup reduced its Immunocore (IMCR) stake by 93% in Q3 2026, selling an estimated $682K and leaving 1,444 shares worth $43.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4752.

Citigroup first reported a position in IMCR in Q4 2022 and has held it in 16 quarters since. The position peaked at $19.9M in Q2 2025. 76 funds tracked by Wall St. Rank hold IMCR as of Q3 2026.

Citigroup held 1,444 shares of Immunocore worth $43.7K as of Q3 2026.
Citigroup sold 20,070 Immunocore shares in Q3 2026, an estimated $682K.
Immunocore made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #4752 holding.
Citigroup first reported a position in Immunocore in Q4 2022 and has held it in 16 quarters since.
Citigroup's Immunocore position peaked at $19.9M in Q2 2025.
76 funds tracked by Wall St. Rank held Immunocore as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.